BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Anulex Technologies, Inc. Resolves FDA Warning Letter


3/21/2012 6:52:52 AM

MINNETONKA, Minn.--(BUSINESS WIRE)--Anulex Technologies, Inc., a privately held medical device manufacturer, has announced the U.S. Food and Drug Administration (FDA) has informed the Company that the actions undertaken to address issues cited in a warning letter from February 2011 have been deemed adequate.

Anulex received an FDA warning letter regarding certain aspects of its post-market study and promotional activities for its legally marketable Xclose™ Tissue Repair System.

“We are encouraged that the FDA has taken a positive view of our corrective actions,” said Jeff Peters, Anulex’s Chief Executive Officer. “Patient safety has always been, and continues to be, our foremost priority. The postmarket study as well as considerable usage outside the study has not resulted in the reported occurrence of any patient safety issues or adverse events beyond those anticipated for procedures involving suturing in general and other orthopedic surgeries. We continue to be committed to conducting every aspect of our business in compliance with applicable regulatory requirements.”

The Xclose™ Tissue Repair System was cleared in 2006 and continues to be available to facilitate surgeons in providing a unique method of approximating soft tissue for procedures such as general and orthopedic surgery.

About Anulex Technologies, Inc.

Anulex Technologies, Inc. is dedicated to the development and commercialization of unique and proprietary soft tissue repair and fixation products. For more information, please visit: www.anulex.com

Contact:

Rotenberg Associates LLC

Amy Rotenberg Esq., 612-336-7705

arotenberg@rotenbergassoc.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES